Login / Signup

Clinical change two years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.

Karen S McCoyJill E BlindTerri JohnsonPatti OlsenLaura RatermanShasha BaiMariah EisnerShahid I SheikhStephan DruhanCody YoungKimberly Pasley
Published in: Pediatric pulmonology (2023)
, subjective reports of clinical status, level of activity, and a reduction in burden of treatment. This article is protected by copyright. All rights reserved.
Keyphrases
  • cystic fibrosis
  • pseudomonas aeruginosa
  • lung function
  • risk factors
  • sleep quality
  • combination therapy